PMID- 28659798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211110
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 8
DP  - 2017
TI  - IL-1beta Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus.
PG  - 363
LID - 10.3389/fphar.2017.00363 [doi]
LID - 363
AB  - Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of 
      people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the 
      majority of all diagnosed cases of diabetes. The course of the T2DM is 
      characterized by insulin resistance and a progressive loss of beta-cell mass. DM is 
      associated with a number of related complications, among which cardiovascular 
      complications and atherosclerosis are the main cause of morbidity and mortality 
      in patients suffering from the disease. DM is acknowledged as a low-grade chronic 
      inflammatory state characterized by the over-secretion of pro-inflammatory 
      cytokines, including interleukin (IL)-1beta, which reinforce inflammatory signals 
      thus contributing to the development of complications. In this context, the 
      pharmacological approaches to treat diabetes should not only correct 
      hyperglycaemia, but also attenuate inflammation and prevent the development of 
      metabolic and cardiovascular complications. Over the last years, novel biological 
      drugs have been developed to antagonize the pathophysiological actions of IL-1beta. 
      The drugs currently used in clinical practice are anakinra, a recombinant form of 
      the naturally occurring IL-1 receptor antagonist, the soluble decoy receptor 
      rilonacept and the monoclonal antibodies canakinumab and gevokizumab. This review 
      will summarize the main experimental and clinical findings obtained with 
      pharmacological IL-1beta inhibitors in the context of the cardiovascular 
      complications of DM, and discuss the perspectives of IL-1beta inhibitors as novel 
      therapeutic tools for treating these patients.
FAU - Peiro, Concepcion
AU  - Peiro C
AD  - Department of Pharmacology, School of Medicine, Universidad Autonoma de 
      MadridMadrid, Spain.
AD  - Instituto de Investigacion Sanitaria Hospital Universitario de La Paz 
      (IdiPAZ)Madrid, Spain.
FAU - Lorenzo, Oscar
AU  - Lorenzo O
AD  - Department of Medicine, School of Medicine, Universidad Autonoma de MadridMadrid, 
      Spain.
AD  - Instituto de Investigacion Sanitaria Fundacion Jimenez DiazMadrid, Spain.
FAU - Carraro, Raffaele
AU  - Carraro R
AD  - Department of Medicine, School of Medicine, Universidad Autonoma de MadridMadrid, 
      Spain.
AD  - Service of Endocrinology, Hospital de La PrincesaMadrid, Spain.
AD  - Instituto de Investigacion Sanitaria Hospital de La PrincesaMadrid, Spain.
FAU - Sanchez-Ferrer, Carlos F
AU  - Sanchez-Ferrer CF
AD  - Department of Pharmacology, School of Medicine, Universidad Autonoma de 
      MadridMadrid, Spain.
AD  - Instituto de Investigacion Sanitaria Hospital Universitario de La Paz 
      (IdiPAZ)Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170613
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC5468794
OTO - NOTNLM
OT  - cardiovascular complications
OT  - diabetes
OT  - inflammation
OT  - interleukin-1 inhibitors
OT  - interleukin-1beta
EDAT- 2017/07/01 06:00
MHDA- 2017/07/01 06:01
PMCR- 2017/06/13
CRDT- 2017/06/30 06:00
PHST- 2017/01/14 00:00 [received]
PHST- 2017/05/26 00:00 [accepted]
PHST- 2017/06/30 06:00 [entrez]
PHST- 2017/07/01 06:00 [pubmed]
PHST- 2017/07/01 06:01 [medline]
PHST- 2017/06/13 00:00 [pmc-release]
AID - 10.3389/fphar.2017.00363 [doi]
PST - epublish
SO  - Front Pharmacol. 2017 Jun 13;8:363. doi: 10.3389/fphar.2017.00363. eCollection 
      2017.